Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Por Persky, Daniel O., Miller, Thomas P., Unger, Joseph M., Spier, Catherine M., Puvvada, Soham, Stea, B. Dino, Press, Oliver W., Constine, Louis S., Barton, Kevin P., Friedberg, Jonathan W., LeBlanc, Michael, Fisher, Richard I.
Publicado no Blood (2015)

Genetic polymorphisms in oxidative stress related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

Por Gustafson, Heather L., Yao, Song, Goldman, Bryan H., Lee, Kristy, Spier, Catherine M., LeBlanc, Michael L., Rimsza, Lisa M., Cerhan, James R., Habermann, Thomas M., Link, Brian K., Maurer, Matthew J., Slager, Susan L., Persky, Daniel O., Miller, Thomas P., Fisher, Richard I., Ambrosone, Christine B., Briehl, Margaret M.
Publicado em 2014

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Por Barr, Paul M., Miller, Thomas P., Friedberg, Jonathan W., Peterson, Derick R., Baran, Andrea M., Herr, Megan, Spier, Catherine M., Cui, Haiyan, Roe, Denise J., Persky, Daniel O., Casulo, Carla, Littleton, Jamie, Schwartz, Mark, Puvvada, Soham, Landowski, Terry H., Rimsza, Lisa M., Dorr, Robert T., Fisher, Richard I., Bernstein, Steven H., Briehl, Margaret M.
Publicado em 2014